Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis

Cancer Research

Volumn 76, Issue 4, 2016, Pages 818-830

  Ye, Long Yun ^a   Chen, Wei ^a   Bai, Xue Li ^a   Xu, Xing Yuan ^a   Zhang, Qi ^a   Xia, Xue Feng ^a   Sun, Xu ^a   Li, Guo Gang ^a   Hu, Qi Da ^a   Fu, Qi Han ^a   Liang, Ting Bo ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT1 PROTEIN; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL EXPANSION; CELL HYPOXIA; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA INDUCED EPITHELIAL MESENCHYMAL TRANSITION; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER METASTASIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MAJOR CLINICAL STUDY; METASTASIS; MONOCYTE DERIVED MACROPHAGE; PORTAL VEIN TUMOR THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR THROMBUS; UPREGULATION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; LIVER TUMOR; METABOLISM; MORTALITY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84960456901     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0977     Document Type: Article

References (50)

1. Lau WY. Management of hepatocellular carcinoma. J R Coll Surg 2002;47:389-99.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, et al. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65.
4. Wu CC,Hsieh SR, Chen JT, HoWL, LinMC, Yeh DC, et al. An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation. Arch Surg 2000;135: 1273-9.
5. Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, et al. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 2006;13:940-6.
6. Ohkubo T, Yamamoto J, Sugawara Y, Shimada K, Yamasaki S, Makuuchi M, et al. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg 2000;191:657-60.
7. Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010;17:2073-80.
8. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990;66:2174-9.
9. Le Treut YP, Hardwigsen J, Ananian P, Saisse J, Gregoire E, Richa H, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg 2006;10: 855-62.
10. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137: 403-10.
11. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009;100:1385-92.
12. Kanda M, Nomoto S, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, et al. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 2008;98:190-6.
13. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Ann Rev Pathol 2006;1:119-50.
14. Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, et al. Lysyl oxidaselike 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology 2014;60:1645-58.
15. Lundgren K, Nordenskjold B, Landberg G. Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer 2009;101: 1769-81.
16. Scheel C, Onder T, Karnoub A, Weinberg RA. Adaptation versus selection: the origins of metastatic behavior. Cancer Res 2007;67:11476-9.
17. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001;98:10356-61.
18. Brabletz T. To differentiate or not-routes towards metastasis. Nat Rev Cancer 2012;12:425-36.
19. Hernandez L, Smirnova T, Kedrin D, Wyckoff J, Zhu L, Stanley ER, et al. The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 2009;69:3221-7.
20. Su S, Liu Q, Chen J, Chen F, He C, Huang D, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014;25:605-20.
21. Kuang DM, Peng C, Zhao Q,WuY, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010;51:154-64.
22. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009;206:1327-37.
23. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
24. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64.
25. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
26. Chen BW, Chen W, Liang H, Liu H, Liang C, Zhi X, et al. Inhibition of mTORC2 induces cell-cycle arrest and enhances the cytotoxicity of doxorubicin by suppressing MDR1 expression in HCC cells. Mol Cancer Therap 2015;14:1805-15.
27. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
28. Matin A, Streete IM, Jamie IM, Truscott RJ, Jamie JF. A fluorescence-based assay for indoleamine 2,3-dioxygenase. Anal Biochem 2006;349:96-102.
29. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008;26:2707-16.
30. Blouin CC, Page EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood 2004;103:1124-30.
31. Hatano N, Itoh Y, Suzuki H, Muraki Y, Hayashi H, Onozaki K, et al. Hypoxia-inducible factor-1alpha (HIF1alpha) switches on transient receptor potential ankyrin repeat 1 (TRPA1) gene expression via a hypoxia response element-like motif to modulate cytokine release. J Biol Chem 2012;287:31962-72.
32. Tong Y, Li QG, Xing TY, Zhang M, Zhang JJ, Xia Q. HIF1 regulates WSB-1 expression to promote hypoxia-induced chemoresistance in hepatocellular carcinoma cells. FEBS Lett 2013;587:2530-5.
33. Zhao Q, Kuang DM,WuY, Xiao X, Li XF, Li TJ, et al. Activated CD69+T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J Immunol 2012;188:1117-24.
34. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116: e74-80.
35. Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D, Dabrowska M. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol 2009;130:338-46.
36. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009;27:669-92.
37. Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31.
38. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res 2006;66:2219-23.
39. Rofstad EK, Galappathi K, Mathiesen B, Ruud EB. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 2007;13:1971-8.
40. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429-37.
41. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741-51.
42. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009;15:195-206.
43. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011;6:e24671.
44. Futagami Y, Sugita S, Vega J, Ishida K, Takase H, Maruyama K, et al. Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells. J Immunol 2007;178:6994-7005.
45. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-44.
46. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gammainducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996;271:17247-52.
47. Barton BE. STAT3: a potential therapeutic target in dendritic cells for the inductionof transplant tolerance. ExpertOpin Ther Targets 2006;10:459-70.
48. Bonifazi P, Zelante T, D'Angelo C, De Luca A, Moretti S, Bozza S, et al. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol 2009;2:362-74.
49. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335-45.
50. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.